Maravai LifeSciences Holdings, Inc.

What they do

Maravai sells critical reagents, consumables and services used by biopharmaceutical companies, emerging biotech firms, diagnostics companies and academic institutions in drug, vaccine and diagnostic development. It reports two segments: TriLink, which supplies mRNA, oligonucleotides, CleanCap capping technology, ModTail poly(A) tail technology, nucleoside triphosphates, specialty enzymes and mRNA manufacturing services, and Cygnus, which supplies host cell protein ELISA kits, impurity detection assays, viral clearance prediction tools and custom analytical services.

Revenue drivers

• TriLink — Largest segment at 64% of 2025 revenue, selling research-use-only and GMP nucleic acid products plus mRNA manufacturing services; Q2 2026 revenue was $34.7 million, up 11.5% year over year.
• Cygnus — Biologics safety testing segment contributing Q2 2026 revenue of $16.8 million, up 2.8% year over year, driven by demand for host cell protein and ELISA kits and distributor ordering timing in China.
• CleanCap COVID-19 vaccine orders — Lumpy, non-recurring high-volume CleanCap analog orders for commercial-phase COVID-19 vaccine programs; $14.3 million was recognized in Q1 2026 and none in Q2 2026.
• ModTail product line — Poly(A) tail modification technology launched commercially about a year ago that has grown to more than 125 active customers; the company does not disclose separate revenue for it.

Recent performance

Q2 2026 total revenue was $51.4 million, up 8.5% from $47.4 million in Q2 2025, with TriLink up 11.5% to $34.7 million and Cygnus up 2.8% to $16.8 million. Six-month 2026 revenue rose 24.4% to $117.3 million, including $14.3 million of high-volume CleanCap COVID vaccine orders in Q1 2026; excluding that, TriLink base revenue grew 13.4%. Q2 2026 net loss was $(21.6) million with Adjusted EBITDA of $8.7 million, versus a net loss of $(69.8) million and negative Adjusted EBITDA of $(10.4) million in Q2 2025. Full year 2025 revenue was $185.7 million, down from $259.2 million in 2024, with a net loss of $130.8 million and operating cash flow of negative $57.6 million. Cash and equivalents were $70.1 million at June 30, 2026 against $146.0 million of long-term debt.

Strategy

Management is focused on growing TriLink's base consumables business, both Discovery mRNA research-use-only materials and GMP products for clinical trials, while expanding Cygnus. The company opened a GMP enzyme manufacturing facility during Q2 2026, which it describes as completing TriLink's integrated portfolio of in vitro transcription raw materials and strengthening its position as a single-source partner from research through commercial manufacturing. It continues to invest in research and development, spending $7.6 million in the first half of 2026 versus $9.8 million a year earlier. On June 2, 2026, it refinanced debt with a new agreement providing a $150.0 million term loan and $30.0 million revolving credit facility maturing in 2032. It ended Q2 2026 with 415 full-time employees, about 26% holding advanced degrees.

Risks

• Customer spending and demand volatility — Revenue depends on biopharmaceutical, biotech and academic customers' spending on outsourced TriLink and Cygnus products and services, which the company lists as a core risk.
• CleanCap COVID revenue concentration — High-volume CleanCap orders for commercial-phase COVID-19 vaccine programs are unpredictable and largely outside the company's control; no further such orders are expected in the remainder of 2026.
• Government policy shifts — Changes in U.S. federal government trade, economic and research funding policies could affect both Maravai's and its customers' operations.
• Organizational change and competition — The company cites unintended consequences from recent organizational changes and workforce reductions, and competition from substantially larger life science, pharmaceutical and biotechnology companies.

Outlook

Management reiterated full year 2026 revenue guidance of $205 million to $215 million and raised 2026 Adjusted EBITDA guidance to $33 million to $35 million. It said no further high-volume CleanCap orders for commercial-phase COVID-19 vaccine programs are expected for the rest of 2026. Guidance is based on the existing business and excludes potential acquisitions or unidentified items. CEO Bernd Brust pointed to GMP manufacturing capacity and ModTail adoption as positioning the company for growth.